A multivariate analysis of tumour biological factors predicting response to cytotoxic treatment in advanced breast cancer

British Journal of Cancer

Volumn 78, Issue 6, 1998, Pages 812-815

  Sjostrom J ^a   Krajewski, S ^b   Franssila, K ^a   Niskanen, E ^a   Wasenius, V M ^a   Nordling, S ^a   Reed, J C ^b   Blomqvist, C ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b BURNHAM INSTITUTE   (United States)

Author keywords

Bax; Chemotherapy; Metastatic breast cancer; Predictive factor; S phase fraction; Tumour biology

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PROGESTERONE RECEPTOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CELL CYCLE S PHASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MULTIVARIATE ANALYSIS; ONCOGENE C ERB; PLOIDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL;

EID: 0031714496     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.584     Document Type: Article

References (14)

1. Aas T, Geisler S, Paulsen T, Borresen-Dale AL, Varhaug JE, Lönning PE and Akslen LA (1996) Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome. Acta Oncol 35(Suppl. 5): 5-8
2. Blomqvist C, Elomaa I, Rissanen P, Hietanen P, Nevasaari K and Helle L (1993) Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin and fluorouracil in metastatic breast cancer: a randomized trial comparing weekly and every-4-week administration. J Clin Oncol 11: 467-473
3. Elston CW and Ellis IO (1991) Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5): 403-410
4. Hietanen P, Blomqvist C, Wasenius V-M, Niskanen E, Franssila K and Nordling S (1995) Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer? Br J Cancer 71: 1029-1032
5. Krajewski S, Bodrug S, Gascoyne R, Berean K, Krajewska M and Reed JC (1994a) Immunohistochemical analysis of mcl-1 and bcl-2 proteins in normal and neoplastic lymph nodes. Am J Pathol 145: 515-525
6. Krajewski S, Krajewska M, Shabaik A, Miyashita T, Wang H-G and Reed JC (1994b) Immunohistochemical determination of in vivo distribution of bax, a dominant inhibitor of bcl-2. Am J Pathol 145: 1323-1333
7. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius V-M, Niskanen E, Nordling S and Reed JC (1995) Reduced expression of proapoptotic gene Bax is associated with poor response rates in combination chemotherapy and short survival in women with metastatic breast adenocarcinoma. Cancer Res 55: 4471-4478
8. Mansour EG, Ravdin PM and Dressler L (1994) Prognostic factors in early breast carcinoma. Cancer 74: 381-400
9. Niskanen E, Franssila K, Blomqvist C, Hietanen P and Wasenius V-M (1997) Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer. Br J Cancer 76: 917-922
10. Reed JC (1994) Bcl-2 and the regulation of programmed cell death. J Cell Biol 124(1-2): 1-6
11. Remvikos Y, Beuzeboc P, Zajdela A, Voillemot N, Magdelenat H and Pouillart P (1989) Correlation of pre-treatment proliferative activity of breast cancer with response to cytotoxic chemotherapy. J Natl Cancer Inst 1: 1383-1387
12. Ro S, Sahin A, Ro J, Fritsche H, Hortobagyi G and Blick M (1990) Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Hum Pathol 21: 787-791
13. Sjöström J and Blomqvist C (1996) Predictive factors for response to cytotoxic treatment in advanced breast cancer. A review. Acta Oncol 35(Suppl. 5): 84-90
14. Verrelle P, Meissonnier F, Fonck Y, Feillel V, Dionet C, Kwiatkowski F, Plagne R and Chassagne J (1991) Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst 83: 111-116